EGFR and neoplasm: Blocking of the EGFR by cetuximab enhanced the expression of the T-cell attracting chemokines but lowered the expression of IL-1β Potentially, this contributes to the intratumoral T cell responses as IL-1β may indirectly suppress the proliferation and function of these T cells via tumor associated fibroblasts that start to express COX-2 and PD-L1 [34].